These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 24345267)

  • 1. The attentional set-shifting test paradigm in rats for the screening of novel pro-cognitive compounds with relevance for cognitive deficits in schizophrenia.
    Denis Goetghebeur PJ; Dias R
    Curr Pharm Des; 2014; 20(31):5060-8. PubMed ID: 24345267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attentional set-shifting in rodents: a review of behavioural methods and pharmacological results.
    Tait DS; Chase EA; Brown VJ
    Curr Pharm Des; 2014; 20(31):5046-59. PubMed ID: 24345263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Putative cognitive enhancers in preclinical models related to schizophrenia: the search for an elusive target.
    Barak S; Weiner I
    Pharmacol Biochem Behav; 2011 Aug; 99(2):164-89. PubMed ID: 21420999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of alpha7 nicotinic acetylcholine receptor agonists on attentional set-shifting impairment in rats.
    Jones KM; McDonald IM; Bourin C; Olson RE; Bristow LJ; Easton A
    Psychopharmacology (Berl); 2014 Feb; 231(4):673-83. PubMed ID: 24057763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MAM-E17 rat model impairments on a novel continuous performance task: effects of potential cognitive enhancing drugs.
    Mar AC; Nilsson SRO; Gamallo-Lana B; Lei M; Dourado T; Alsiö J; Saksida LM; Bussey TJ; Robbins TW
    Psychopharmacology (Berl); 2017 Oct; 234(19):2837-2857. PubMed ID: 28744563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive validity of a MK-801-induced cognitive impairment model in mice: implications on the potential limitations and challenges of modeling cognitive impairment associated with schizophrenia preclinically.
    Brown JW; Rueter LE; Zhang M
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Mar; 49():53-62. PubMed ID: 24269664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of α5 GABAA receptor agonists in the treatment of cognitive deficits in schizophrenia.
    Gill KM; Grace AA
    Curr Pharm Des; 2014; 20(31):5069-76. PubMed ID: 24345268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracellular signaling and approaches to the treatment of schizophrenia and associated cognitive impairment.
    Snyder GL; Vanover KE
    Curr Pharm Des; 2014; 20(31):5093-103. PubMed ID: 24345266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythropoietin reverses the attentional set-shifting impairment in a rodent schizophrenia disease-like model.
    Goetghebeur PJ; Lerdrup L; Sylvest A; Dias R
    Psychopharmacology (Berl); 2010 Dec; 212(4):635-42. PubMed ID: 20734030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of a 5-HT5A receptor antagonist in a ketamine-based rat model of cognitive dysfunction and the negative symptoms of schizophrenia.
    Nikiforuk A; Hołuj M; Kos T; Popik P
    Neuropharmacology; 2016 Jun; 105():351-360. PubMed ID: 26826431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Executive function in schizophrenia: what impact do antipsychotics have?
    O'Grada C; Dinan T
    Hum Psychopharmacol; 2007 Aug; 22(6):397-406. PubMed ID: 17579928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism.
    Neill JC; Barnes S; Cook S; Grayson B; Idris NF; McLean SL; Snigdha S; Rajagopal L; Harte MK
    Pharmacol Ther; 2010 Dec; 128(3):419-32. PubMed ID: 20705091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Editorial: Current pro-cognitive therapeutic strategies for improved pharmacological treatment in schizophrenia.
    Wadenberg ML
    Curr Pharm Des; 2014; 20(31):5045. PubMed ID: 24345264
    [No Abstract]   [Full Text] [Related]  

  • 14. May non-antipsychotic drugs improve cognition of schizophrenia patients?
    Buoli M; Altamura AC
    Pharmacopsychiatry; 2015 Mar; 48(2):41-50. PubMed ID: 25584772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nicotine improves performance in an attentional set shifting task in rats.
    Allison C; Shoaib M
    Neuropharmacology; 2013 Jan; 64():314-20. PubMed ID: 22776507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology.
    Neill JC; Grayson B; Kiss B; Gyertyán I; Ferguson P; Adham N
    Eur Neuropsychopharmacol; 2016 Jan; 26(1):3-14. PubMed ID: 26655189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic infusion of PCP via osmotic mini-pumps: a new rodent model of cognitive deficit in schizophrenia characterized by impaired attentional set-shifting (ID/ED) performance.
    Pedersen CS; Goetghebeur P; Dias R
    J Neurosci Methods; 2009 Dec; 185(1):66-9. PubMed ID: 19761795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting drug efficacy for cognitive deficits in schizophrenia.
    Hagan JJ; Jones DN
    Schizophr Bull; 2005 Oct; 31(4):830-53. PubMed ID: 16177277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amisulpride alleviates chronic mild stress-induced cognitive deficits: Role of prefrontal cortex microglia and Wnt/β-catenin pathway.
    Mohamed AM; Habib MZ; Ebeid MA; Abdelraouf SM; El Faramawy Y; Aboul-Fotouh S; Magdy Y
    Eur J Pharmacol; 2020 Oct; 885():173411. PubMed ID: 32800810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impairment in perceptual attentional set-shifting following PCP administration: a rodent model of set-shifting deficits in schizophrenia.
    Egerton A; Reid L; McKerchar CE; Morris BJ; Pratt JA
    Psychopharmacology (Berl); 2005 Apr; 179(1):77-84. PubMed ID: 15682304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.